Business Context and Reporting Period
This Form 8-K filing by Anthem, Inc. (now Elevance Health, Inc.) reports a capital market event occurring on September 4, 2019, with the report filed on September 9, 2019. The filing details the closing of a public offering of senior notes.
Key Financial Metrics
The Company completed the sale of three series of senior notes with an aggregate principal amount of $2.5 billion. The net proceeds received were approximately $2,473 million after deducting underwriting discounts and offering expenses.
| Note Series | Principal Amount | Coupon Rate | Maturity Date |
|---|---|---|---|
| 2025 Notes | $850 million | 2.375% | January 15, 2025 |
| 2029 Notes | $825 million | 2.875% | September 15, 2029 |
| 2049 Notes | $825 million | 3.700% | September 15, 2049 |
The filing text does not provide specific values for revenue, profit, operating cash flow, margins, or existing debt levels outside of this new issuance.
Material Changes
The primary material change is the increase in long-term debt obligations by $2.5 billion in principal. This transaction represents a significant shift in the Company's capital structure, adding fixed-income liabilities with varying maturities ranging from 2025 to 2049.
Guidance, Outlook, and Management Commentary
Management intends to use the net proceeds for working capital and general corporate purposes. Specific uses include:
- Repurchasing common stock pursuant to the share repurchase program.
- Repayment of short-term and long-term debt.
- Funding acquisitions.
The Indenture governing the notes does not prohibit or limit the incurrence of additional indebtedness. The notes include a change of control provision requiring an offer to purchase the notes at 101% of principal plus accrued interest if the Company undergoes a change of control and the notes are downgraded below investment grade by all three major rating agencies.
Investor Verification Checklist
- Verify the exact net proceeds of $2,473 million against the $2.5 billion principal to confirm underwriting costs.
- Review the Company's current debt maturity schedule to assess the impact of the new 2025, 2029, and 2049 maturities on liquidity.
- Confirm the status of the share repurchase program to determine if proceeds will be deployed immediately.
- Check current credit ratings from Moody's, S&P, and Fitch to evaluate the risk of the change of control provision being triggered.
- Examine the Underwriting Agreement (Exhibit 1.1) for any specific covenants or restrictions not detailed in the summary.